Abstract
In silico methodologies have opened new avenues of research to understanding and predicting drug resistance, a pressing health issue that keeps rising at alarming pace. Sequence-based interpretation systems are routinely applied in clinical context in an attempt to predict mutation-based drug resistance and thus aid the choice of the most adequate antibiotic and antiviral therapy. An important limitation of approaches based on genotypic data exclusively is that mutations are not considered in the context of the three-dimensional (3D) structure of the target. Structure-based in silico methodologies are inherently more suitable to interpreting and predicting the impact of mutations on target-drug interactions, at the cost of higher computational and time demands when compared with sequence-based approaches. Herein, we present a fast, computationally inexpensive, sequence-to-structure-based approach to drug resistance prediction, which makes use of 3D protein structures encoded by input target sequences to draw binding-site comparisons with susceptible templates. Rather than performing atom-by-atom comparisons between input target and template structures, our workflow generates and compares Molecular Interaction Fields (MIFs) that map the areas of energetically favorable interactions between several chemical probe types and the target binding site. Quantitative, pairwise dissimilarity measurements between the target and the template binding sites are thus produced. The method is particularly suited to understanding changes to the 3D structure and the physicochemical environment introduced by mutations into the target binding site. Furthermore, the workflow relies exclusively on freeware, making it accessible to anyone. Using four datasets of known HIV-1 protease sequences as a case-study, we show that our approach is capable of correctly classifying resistant and susceptible sequences given as input. Guided by ROC curve analyses, we fined-tuned a dissimilarity threshold of classification that results in remarkable discriminatory performance (accuracy ≈ ROC AUC ≈ 0.99), illustrating the high potential of sequence-to-structure-, MIF-based approaches in the context of drug resistance prediction. We discuss the complementarity of the proposed methodology to existing prediction algorithms based on genotypic data. The present work represents a new step toward a more comprehensive and structurally-informed interpretation of the impact of genetic variability on the response to HIV-1 therapies.
Highlights
Drug resistance is one of the greatest threats of the twenty first century
This section describes the materials and methods employed in (1) the preparation of sequence datasets with various levels of resistance to protease inhibitors (PIs); (2) frequency analysis of major and minor mutations in the sequence datasets in (1); (3) the structural modeling of the reference structure used as template for subsequent modeling of HIV-1 protease (HIV1-PR) structures corresponding to each sequence in the datasets; (4) the core components of the proposed algorithm, including the calculation and comparison of pairwise Molecular Interaction Field points between the resulting structural models and the selected naïve template structure; and (5) the performance metrics used to test and evaluate the predictive power of the developed structure-based drug-resistance classification algorithm
Resistance to PIs develops upon accumulation of mutations that increasingly impact the structure of HIV1-PR, resulting in highly-resistant variants of human immunodeficiency virus (HIV)-1
Summary
The problem resides in the development and spread of resistance-conferring mechanisms among infectious pathogens such as viruses and other microbial targets (McKeegan et al, 2002). The selection of random mutations stands out as one of the main mechanisms of acquiring resistance, relevant in viruses which mutate at high frequencies. The extreme variability and rapid mutational spectrum of viral genomes, ongoing viral replication, and prolonged drug exposure linked with the selection and widespread of new drug-resistant strains is still a matter of great concern and importance, in immunocompromised populations (Strasfeld and Chou, 2010; Mason et al, 2018). A priori understanding and prediction of resistance against drug targets is of paramount importance toward developing more effective and longer lasting treatment options and regimens
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.